PHARMACOLOGY IS THE COURSE WHERE NURSING STUDENTS FIND OUT HOW DEEP THE WORK GOES.
You open the textbook expecting drug names and dose ranges. What you find instead is an entire universe of clinical reasoning layered inside every medication interaction, every contraindication, every patient education point, and every adverse effect that separates a therapeutic outcome from a preventable tragedy.
Pharmacology and the Nursing Process has been one of the most widely used pharmacology textbooks in nursing education for a generation — and for good reason. Lilley, Rainforth Collins, and Snyder do not just teach you drug classifications. They teach you how to think about drugs as a nurse. How to apply the nursing process to pharmacological care. How to assess before administering, how to plan for the expected and unexpected, how to implement safely, and how to evaluate whether what you gave actually did what it was supposed to do.
The 11th edition continues that tradition with updated drug information, current clinical guidelines, and the kind of patient-centered pharmacological reasoning that nursing boards and real clinical practice demand equally.
This test bank was built to help you master it.
Not just pass the quiz at the end of each chapter. Master it — in the way that makes you a safe, knowledgeable, clinically confident nurse who understands not just what drug to give but why, when, how, and what to watch for afterward.
THE REAL REASON PHARMACOLOGY IS HARD
Most nursing students do not struggle with pharmacology because the content is too difficult. They struggle because they approach it the wrong way.
Here is how most students study pharmacology. They read the chapter. They highlight the drug names. They memorize the drug class. They note the common side effects and the major contraindications. They make flashcards. They feel prepared. Then they sit for an exam that asks them a clinical scenario question — a patient with a specific condition, on specific other medications, with a specific set of symptoms — and suddenly the memorized facts do not organize themselves into a clinical answer quickly enough.
The exam is not asking what drug X does. It is asking what the nurse does when the patient is on drug X, has renal impairment, and is about to receive drug Y. It is asking what assessment finding should make the nurse withhold the medication. It is asking what the patient needs to know before they go home with this prescription. It is asking what the earliest sign of toxicity looks like and what the nurse does when they see it.
That is applied pharmacological reasoning. It is the only kind that matters in nursing practice. And it is built through practice — through working question after question, scenario after scenario, until the reasoning becomes instinctive.
That is what this test bank builds.
Every question in this resource is written the way pharmacology is actually tested — in the clinical scenario format that requires you to apply your drug knowledge to a patient situation, not just recall a fact in isolation. Every rationale explains the reasoning, not just the answer. Every wrong answer is analyzed so you understand not just what you should have chosen but why the other options fail clinically.
Work through this test bank consistently and pharmacology will stop feeling like memorization and start feeling like clinical reasoning. That is the transformation this course is designed to produce — and this test bank is designed to accelerate.
THE NURSING PROCESS FRAMEWORK THAT ORGANIZES EVERYTHING
One of the things that makes Lilley’s approach to pharmacology distinctive — and distinctively useful for nursing students — is the consistent application of the nursing process as the organizing framework for every drug class and every clinical scenario.
It sounds simple. But its implications are profound.
Assessment comes first — always. Before you administer any medication, you gather data. You check the patient’s current vital signs, renal and hepatic function, current medication list, allergies, weight, pregnancy status, and relevant lab values. You identify contraindications. You flag drug interactions. You assess the patient’s understanding of their medication regimen and their ability to adhere to it. In this test bank, questions about assessment appear constantly — because unsafe medication practice almost always begins with inadequate assessment.
Diagnosis shapes the pharmacological plan. Nursing diagnoses in the context of pharmacology include deficient knowledge about medication therapy, risk for injury related to adverse drug effects, impaired adherence related to side effect burden, and risk for toxicity related to narrow therapeutic index. Questions that ask you to identify the priority nursing diagnosis for a patient on a specific medication are testing whether you understand the pharmacological risk profile of that drug deeply enough to anticipate the most significant nursing concern.
Planning requires anticipation of both therapeutic effects and adverse effects. The nursing care plan for a patient on anticoagulant therapy looks very different from the care plan for a patient on lithium, which looks different from the care plan for a patient on chemotherapy. Planning questions ask you to identify what needs to be in place before, during, and after medication administration — and this test bank tests that planning framework across every major drug class.
Implementation is where safety lives. The rights of medication administration — right patient, right drug, right dose, right route, right time, right documentation, and the additional rights that have been added to the traditional five — are foundational. But implementation in pharmacology goes much deeper. It includes the timing of medication relative to food or other medications, the specific technique required for certain routes of administration, the monitoring required during IV drug infusion, the environmental modifications that reduce drug-related injury risk. Implementation questions in this test bank are specific, clinical, and scenario-based.
Evaluation closes the loop — and opens the next one. Did the drug work? Is the patient showing signs of therapeutic response? Are adverse effects emerging that require dose adjustment or drug discontinuation? Is the patient understanding their medication regimen well enough to continue it safely at home? Evaluation questions are among the most important in clinical pharmacology — and they are consistently underrepresented in how students prepare for exams. This test bank ensures they are not underrepresented in your preparation.
📦 EVERYTHING INSIDE YOUR PURCHASE
Here is precisely what you receive:
- A comprehensive bank of multiple-choice questions covering every unit and chapter of the 11th edition
- Questions written in NCLEX-RN clinical scenario format with the nursing process framework integrated throughout
- Every question paired with a clearly identified correct answer
- Detailed rationales explaining the pharmacological, physiological, and nursing process reasoning behind each answer — including specific analysis of why each wrong answer is clinically incorrect
- Questions covering drug mechanisms, therapeutic indications, contraindications, adverse effects, drug interactions, patient education, toxicity monitoring, and the full nursing process applied to pharmacological care
- Both PDF and Word formats included for flexible, multi-device studying
- Content built exclusively around the 11th edition — fully updated, evidence-aligned, and NCLEX-relevant
📚 COMPLETE CONTENT COVERAGE
Every unit. Every chapter. Every drug class and every nursing process concept in the 11th edition.
Unit 1 — Pharmacology Basics
- Introduction to pharmacology — definitions, sources of drug information, drug legislation
- Drug nomenclature — chemical, generic, and brand names — clinical significance
- The nursing process applied to pharmacology — ADPIE across drug therapy
- Pharmacokinetics — absorption, distribution, metabolism, excretion — nursing implications
- Routes of administration and their pharmacokinetic implications
- Pharmacodynamics — receptor theory, agonists and antagonists, dose-response relationships
- Drug interactions — pharmacokinetic and pharmacodynamic interactions — clinical significance
- Adverse drug reactions — types, severity classification, reporting, and nursing response
- Medication errors — causes, types, prevention strategies, and nursing accountability
- The rights of medication administration — the traditional five and the expanded framework
- Special populations in pharmacology — pediatric, geriatric, pregnant, and breastfeeding patients
- Pharmacogenomics — individualized drug therapy and nursing implications
- Herbal and natural health products — safety, interactions, and nursing counseling
- Drug calculations — weight-based dosing, unit conversions, IV infusion rate calculations
- High-alert medications — institutional safeguards and nursing vigilance
Unit 2 — Autonomic and Central Nervous System Drugs
Cholinergic Drugs
- Cholinergic agonists — direct-acting and indirect-acting — mechanism, indications, adverse effects
- Acetylcholinesterase inhibitors — myasthenia gravis treatment, Alzheimer’s disease — monitoring and nursing care
- Cholinergic crisis versus myasthenic crisis — differentiation and emergency management
Anticholinergic Drugs
- Muscarinic antagonists — atropine, scopolamine, glycopyrrolate — indications and adverse effects
- Anticholinergic toxidrome — recognition and management
- Anticholinergic medications in older adults — Beers Criteria considerations
Adrenergic Drugs
- Adrenergic agonists — alpha and beta receptor specificity, clinical applications
- Epinephrine — anaphylaxis management, cardiac arrest, and nursing administration
- Norepinephrine and dopamine — vasopressor therapy and nursing monitoring
- Beta-2 agonists — bronchodilation, uterine relaxation — clinical use
Adrenergic Blocking Drugs
- Alpha-1 blockers — hypertension and benign prostatic hyperplasia — nursing considerations
- Beta-blockers — cardiovascular indications, contraindications, withdrawal precautions
- Non-selective versus selective beta-blockade — clinical implications
Central Nervous System Depressants
- Sedative-hypnotics — benzodiazepines, non-benzodiazepine hypnotics — dependence risk and nursing counseling
- General anaesthesia — phases, reversal agents, and perioperative nursing care
- Opioid analgesics — mechanism, equianalgesic dosing, adverse effects, naloxone reversal
- Opioid use disorder — medication-assisted treatment in nursing practice
- Non-opioid analgesics — NSAIDs, acetaminophen — mechanism, toxicity, and nursing monitoring
- Migraine pharmacotherapy — triptans, ergotamines, and preventive agents
Antiseizure Drugs
- First-generation antiepileptics — phenytoin, phenobarbital, valproic acid — monitoring and toxicity
- Phenytoin — therapeutic range, gingival hyperplasia, cardiac effects, IV administration precautions
- Second-generation antiepileptics — lamotrigine, levetiracetam, topiramate — nursing considerations
- Status epilepticus — pharmacological management and nursing priorities
- Antiepileptic therapy in pregnancy — teratogenicity and clinical decision making
Drugs for Parkinson’s Disease
- Levodopa-carbidopa — mechanism, on-off phenomenon, dietary tyramine interaction
- Dopamine agonists — pramipexole, ropinirole — adverse effects and nursing monitoring
- MAO-B inhibitors — selegiline, rasagiline — interaction precautions
- Anticholinergic agents in Parkinson’s disease
Psychotherapeutic Drugs
- Antidepressants — SSRIs, SNRIs, TCAs, MAOIs — mechanisms, nursing monitoring, and patient education
- Serotonin syndrome — drug combinations that cause it, recognition, and emergency response
- Antipsychotics — first and second generation — EPS, NMS, metabolic effects, clozapine monitoring
- Mood stabilizers — lithium therapeutic monitoring, toxicity levels, dietary and fluid education
- Anxiolytics — benzodiazepines, buspirone, clinical applications and patient counseling
- Drugs for ADHD — stimulants and non-stimulants — monitoring, abuse potential, and nursing education
- Drugs for Alzheimer’s disease — acetylcholinesterase inhibitors, memantine — expectations and monitoring
Unit 3 — Cardiovascular and Renal Drugs
Antihypertensive Drugs
- Diuretics — thiazide, loop, potassium-sparing — mechanism, electrolyte effects, nursing monitoring
- ACE inhibitors — mechanism, cough, angioedema, renal protection, and nursing education
- Angiotensin receptor blockers — clinical profile and comparison with ACE inhibitors
- Calcium channel blockers — dihydropyridines versus non-dihydropyridines, grapefruit interaction
- Beta-blockers in hypertension — indication, contraindications, withdrawal precautions
- Alpha-2 agonists — clonidine — rebound hypertension risk and nursing counseling
- Direct vasodilators — hydralazine, minoxidil — clinical use and adverse effects
- Hypertensive emergency versus urgency — pharmacological management
Antianginal Drugs
- Nitrates — mechanism, tolerance, headache, hypotension, storage and administration requirements
- Sublingual nitroglycerin — patient education on dose frequency and emergency use
- Beta-blockers and calcium channel blockers in angina — stable versus variant angina applications
Antidysrhythmic Drugs
- Vaughan Williams classification — clinical significance and nursing application
- Class I agents — sodium channel blockers — lidocaine, procainamide — monitoring
- Class II agents — beta-blockers — ventricular rate control
- Class III agents — amiodarone — pulmonary, thyroid, hepatic, and photosensitivity monitoring
- Amiodarone — the most complex drug in nursing practice — comprehensive monitoring requirements
- Class IV agents — non-dihydropyridine calcium channel blockers
- Digoxin — therapeutic range, toxicity signs, electrolyte interactions, pulse holding parameters
Heart Failure Drugs
- ACE inhibitors and ARBs in heart failure — mortality benefit and monitoring
- Beta-blockers in heart failure — carvedilol, metoprolol succinate — initiation precautions
- Diuretics in heart failure — loop diuretics, daily weight monitoring, output assessment
- Digoxin in heart failure — current indications and monitoring
- Aldosterone antagonists — spironolactone, eplerenone — potassium monitoring
- Neprilysin inhibitors — sacubitril/valsartan — clinical profile and nursing considerations
- Inotropic agents — dobutamine, milrinone — IV monitoring and nursing care
Anticoagulant and Antiplatelet Drugs
- Unfractionated heparin — weight-based dosing, aPTT monitoring, protamine reversal, HIT risk
- Low molecular weight heparins — enoxaparin — subcutaneous administration, anti-Xa monitoring
- Warfarin — mechanism, INR monitoring, dietary vitamin K consistency, drug interactions, bleeding precautions
- Direct oral anticoagulants — dabigatran, rivaroxaban, apixaban, edoxaban — advantages, limitations, reversal agents
- Antiplatelet drugs — aspirin, clopidogrel, ticagrelor — mechanisms and dual antiplatelet therapy
- Thrombolytics — alteplase — indications, contraindications, and nursing administration during stroke or MI
Antilipemic Drugs
- Statins — mechanism, myopathy risk, CK monitoring, hepatotoxicity, and patient education
- Ezetimibe — mechanism and combination therapy
- PCSK9 inhibitors — evolocumab, alirocumab — injectable administration and patient education
- Bile acid sequestrants and niacin — clinical use and nursing considerations
- Triglyceride-lowering agents — fibrates, omega-3 fatty acids
Diuretics
- Loop diuretics — furosemide — mechanism, peak action timing, electrolyte monitoring
- Thiazide diuretics — hydrochlorothiazide — electrolyte effects and drug interactions
- Potassium-sparing diuretics — spironolactone, triamterene — hyperkalemia risk
- Combination diuretic therapy — clinical rationale and monitoring
Unit 4 — Drugs Affecting the Respiratory System
- Bronchodilators — SABAs, LABAs — proper inhaler technique, frequency limits, spacer use
- Anticholinergic bronchodilators — ipratropium, tiotropium — clinical use and patient education
- Inhaled corticosteroids — anti-inflammatory mechanism, oral candidiasis prevention, adrenal suppression risk
- Leukotriene modifiers — montelukast — delayed onset and patient education
- Mast cell stabilizers — cromolyn — prophylactic use and administration timing
- Phosphodiesterase inhibitors — theophylline — narrow therapeutic range, toxicity signs, drug interactions
- Biologics for severe asthma — omalizumab, mepolizumab — subcutaneous administration and monitoring
- Decongestants — pseudoephedrine, oxymetazoline — rebound congestion and cardiovascular effects
- Antihistamines — first and second generation — sedation, anticholinergic effects, and patient counseling
- Antitussives and expectorants — clinical use and nursing considerations
- Drugs for pulmonary arterial hypertension — bosentan, sildenafil — hepatotoxicity and drug interactions
- Drugs for COPD — combination inhaler therapy, exacerbation management, and patient education
- Respiratory drugs in special populations — pregnancy, paediatrics, and older adults
Unit 5 — Drugs Affecting the Gastrointestinal System
- Antacids — mechanism, interactions with other medications, and timing of administration
- H2 receptor antagonists — mechanism, drug interactions, and clinical applications
- Proton pump inhibitors — mechanism, long-term use concerns, C. diff risk, and patient education
- Antiemetics — ondansetron, prochlorperazine, metoclopramide, scopolamine — clinical applications
- Prokinetic agents — metoclopramide — tardive dyskinesia risk with long-term use
- Laxatives — bulk-forming, stimulant, osmotic, stool softeners — appropriate use and patient education
- Antidiarrheals — loperamide, bismuth subsalicylate — clinical use and precautions
- Drugs for inflammatory bowel disease — mesalamine, corticosteroids, immunomodulators, biologics
- Drugs for irritable bowel syndrome — antispasmodics, lubiprostone, linaclotide
- Drugs for Clostridium difficile infection — vancomycin, fidaxomicin, metronidazole
- Drugs for peptic ulcer disease — triple therapy, bismuth quadruple therapy — adherence and completion
- Drugs for hepatic conditions — lactulose, rifaximin in hepatic encephalopathy
Unit 6 — Anti-infective Drugs
Antibiotics
- Principles of antibiotic therapy — spectrum, bactericidal versus bacteriostatic, culture and sensitivity
- Antibiotic stewardship — the nurse’s role in reducing inappropriate antibiotic use
- Penicillins — mechanism, allergy cross-reactivity, probenecid interaction
- Cephalosporins — generations, cross-sensitivity with penicillins, clinical applications
- Carbapenems — imipenem, meropenem — spectrum and nursing monitoring
- Monobactams — aztreonam — use in penicillin allergy
- Vancomycin — mechanism, red man syndrome prevention, trough monitoring, nephrotoxicity
- Vancomycin-resistant enterococcus — clinical significance and nursing precautions
- Aminoglycosides — gentamicin, tobramycin — nephrotoxicity, ototoxicity, peak and trough monitoring
- Fluoroquinolones — mechanism, black box warnings, tendon rupture, photosensitivity, QTc prolongation
- Tetracyclines — mechanism, food and mineral interactions, photosensitivity, use in pregnancy
- Macrolides — azithromycin, clarithromycin — QTc prolongation, drug interactions
- Sulfonamides — trimethoprim-sulfamethoxazole — allergy, folate interference, and clinical use
- Clindamycin — mechanism, pseudomembranous colitis risk, and patient education
- Linezolid — mechanism, serotonin syndrome risk, MAO inhibition, and dietary restrictions
- Metronidazole — mechanism, disulfiram-like reaction with alcohol, clinical use
- Daptomycin — mechanism, myopathy monitoring, and CPK level assessment
Antifungal Drugs
- Amphotericin B — nephrotoxicity, infusion reactions, premedication protocols, and IV monitoring
- Azoles — fluconazole, itraconazole, voriconazole — hepatotoxicity, drug interactions, and QTc effects
- Echinocandins — caspofungin, micafungin — clinical use and nursing monitoring
Antiviral Drugs
- Drugs for herpes viruses — acyclovir, valacyclovir — renal hydration requirements and patient education
- Drugs for influenza — oseltamivir, zanamivir — timing of initiation, resistance, and administration
- Antiretroviral therapy — NRTI, NNRTI, PI, integrase inhibitors — adherence, resistance, and nursing support
- Pre-exposure prophylaxis — tenofovir/emtricitabine — patient education and monitoring
- Drugs for COVID-19 — nirmatrelvir/ritonavir, remdesivir — current clinical context
- Drugs for hepatitis B and C — nucleoside analogues, direct-acting antivirals — monitoring and nursing care
Antimycobacterial Drugs
- Isoniazid — hepatotoxicity, peripheral neuropathy, pyridoxine supplementation, and patient education
- Rifampin — drug interactions, orange discoloration of body fluids, and patient education
- Ethambutol — optic neuritis monitoring and patient counseling
- Pyrazinamide — hepatotoxicity and uric acid monitoring
- Directly observed therapy — the nurse’s role in tuberculosis treatment adherence
Antiparasitic Drugs
- Antimalarials — chloroquine, mefloquine, artemisinin-based combination therapy
- Antihelminthic drugs — mebendazole, albendazole — clinical use and patient education
Unit 7 — Immunological Drugs
- Vaccines — immunization schedule, types, administration, adverse effects, and anaphylaxis management
- Immunosuppressants — corticosteroids, calcineurin inhibitors, antimetabolites — transplant nursing
- Tacrolimus and cyclosporine — therapeutic drug monitoring, nephrotoxicity, and infection risk
- Mycophenolate — teratogenicity, GI effects, and blood count monitoring
- Biologics and monoclonal antibodies — infliximab, adalimumab, rituximab — infusion reactions and infection risk
- Colony-stimulating factors — filgrastim, epoetin — clinical use, bone pain, and monitoring
- Immunoglobulins — IVIG indications, infusion monitoring, and nursing care
Unit 8 — Antineoplastic Drugs
- Principles of cancer pharmacology — cell cycle specificity, drug resistance, combination chemotherapy
- Safe handling of cytotoxic drugs — PPE requirements, spill management, and nursing safety
- Alkylating agents — cyclophosphamide, cisplatin — nephrotoxicity, hemorrhagic cystitis, neurotoxicity
- Antimetabolites — methotrexate, 5-fluorouracil — mucositis, myelosuppression, and leucovorin rescue
- Antitumour antibiotics — doxorubicin — cardiotoxicity monitoring, cumulative dose limits, vesicant precautions
- Vinca alkaloids — vincristine, vinblastine — neurotoxicity, constipation, and extravasation risk
- Taxanes — paclitaxel, docetaxel — hypersensitivity reactions, neuropathy, and premedication protocols
- Platinum compounds — cisplatin — nephrotoxicity, ototoxicity, and hydration protocols
- Targeted therapies — imatinib, erlotinib, trastuzumab — mechanisms and nursing monitoring
- Immunotherapy — checkpoint inhibitors — pembrolizumab, nivolumab — immune-related adverse events
- Hormonal antineoplastic agents — tamoxifen, aromatase inhibitors — long-term management and patient education
- Managing chemotherapy adverse effects — nausea, mucositis, myelosuppression, alopecia — nursing interventions
- Oncological emergencies — febrile neutropenia, tumour lysis syndrome — recognition and nursing response
Unit 9 — Endocrine and Metabolic Drugs
Pituitary Drugs
- Anterior pituitary hormones — growth hormone, gonadotropins — clinical applications
- Posterior pituitary hormones — ADH, oxytocin — clinical uses and nursing monitoring
Thyroid and Antithyroid Drugs
- Levothyroxine — administration timing, drug interactions, therapeutic monitoring, and patient education
- Propylthiouracil and methimazole — agranulocytosis risk, monitoring, and patient counseling
- Radioactive iodine — nursing considerations and radiation precautions
Antidiabetic Drugs
- Insulin — types, onset-peak-duration profiles, mixing, injection technique, rotation, hypoglycemia management
- Insulin pens and pumps — patient education and nursing oversight
- Sulfonylureas — glipizide, glimepiride — hypoglycemia risk and patient education
- Biguanides — metformin — lactic acidosis risk, contrast media interaction, and patient counseling
- Thiazolidinediones — pioglitazone — heart failure risk and hepatic monitoring
- DPP-4 inhibitors — sitagliptin, saxagliptin — clinical profile and nursing considerations
- GLP-1 receptor agonists — liraglutide, semaglutide — weight loss, GI effects, pancreatitis risk
- SGLT2 inhibitors — empagliflozin, canagliflozin — genitourinary infections, DKA risk, cardiovascular benefits
- Alpha-glucosidase inhibitors — acarbose — GI effects and administration timing
- Pramlintide — clinical use and hypoglycemia risk with concurrent insulin
- Diabetic ketoacidosis — insulin drip management and nursing monitoring
- Hypoglycaemia management — oral glucose, glucagon administration
Adrenal Drugs
- Corticosteroids — anti-inflammatory mechanism, systemic effects, tapering requirements, adrenal suppression
- Mineralocorticoids — fludrocortisone — clinical use and monitoring
Osteoporosis Drugs
- Bisphosphonates — administration requirements, esophageal precautions, osteonecrosis of the jaw
- Denosumab — injection technique, hypocalcemia risk, and monitoring
- Selective estrogen receptor modulators — raloxifene — VTE risk and patient counseling
- Teriparatide — injection administration and osteosarcoma black box warning
Unit 10 — Women’s and Men’s Health Drugs
Women’s Health
- Oral contraceptives — combined and progestin-only — mechanism, missed dose management, drug interactions
- Emergency contraception — mechanism, timing, and patient counseling
- Hormone replacement therapy — indications, risks, benefits, and nursing education
- Drugs for menopause symptoms — pharmacological and non-pharmacological options
- Fertility drugs — clomiphene, gonadotropins — multiple gestation risk and monitoring
- Uterotonic drugs — oxytocin, methylergonovine, misoprostol — indications and nursing monitoring
- Tocolytic drugs — nifedipine, terbutaline — preterm labour management and nursing care
- Drugs for endometriosis — GnRH agonists, progestins — adverse effects and patient education
- Drugs for premenstrual dysphoric disorder
Men’s Health
- Testosterone replacement — forms, indications, cardiovascular risk, and monitoring
- Drugs for benign prostatic hyperplasia — alpha-1 blockers, 5-alpha reductase inhibitors — clinical profile
- Drugs for erectile dysfunction — PDE5 inhibitors — nitrate contraindication, cardiovascular precautions
- Drugs for prostate cancer — androgen deprivation therapy — hot flashes, bone density, and cardiovascular effects
Unit 11 — Topical and Ophthalmic Drugs
- Topical dermatological drugs — corticosteroids, retinoids, antifungals, antibiotics
- Wound care pharmacology — antiseptics, debridement agents, and healing promoters
- Drugs for acne — topical and systemic — isotretinoin REMS program and pregnancy risk
- Ophthalmic drugs — anti-infective, anti-inflammatory, antiglaucoma agents
- Beta-blockers for glaucoma — systemic absorption and nursing considerations
- Prostaglandin analogues — latanoprost — administration technique and eye colour change
- Otic drugs — eardrops — administration technique and contraindications
Unit 12 — Emergency and Critical Care Pharmacology
- Cardiac arrest pharmacology — epinephrine, amiodarone, vasopressin — ACLS protocols and nursing role
- Vasopressors and inotropes — norepinephrine, vasopressin, dobutamine — haemodynamic monitoring
- Thrombolytics in acute stroke and MI — alteplase — administration windows, contraindications, and nursing monitoring
- Reversal agents — protamine for heparin, vitamin K and FFP for warfarin, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors
- Naloxone — opioid overdose reversal — dosing, repeat dosing requirements, and monitoring
- Flumazenil — benzodiazepine reversal — seizure risk and monitoring
- Neuromuscular blocking agents — succinylcholine, rocuronium — safety requirements and reversal
- Sedation in critical care — propofol, dexmedetomidine, midazolam — assessment and monitoring
- Pain management in critical care — fentanyl, morphine, hydromorphone — IV titration and safety
🎯 WHO THIS TEST BANK IS FOR
Undergraduate nursing students currently enrolled in a pharmacology course using Lilley’s 11th edition who want comprehensive, chapter-by-chapter exam practice that matches the clinical scenario format of their course examinations.
Students preparing for pharmacology unit exams, midterms, and final examinations who want to move beyond memorization and build the applied drug knowledge that exams and clinical practice demand.
NCLEX-RN candidates who know that pharmacological and parenteral therapies is one of the most heavily weighted content areas on the licensing examination and want focused, high-quality pharmacology practice built around the nursing process framework.
Nurses returning to practice or transitioning to new clinical areas who want to review and consolidate their pharmacological knowledge base systematically before entering new clinical environments.
Nursing students in pharmacology-intensive courses such as critical care, oncology nursing, or cardiovascular nursing who want drug class-specific deep-dive practice.
Nursing faculty teaching pharmacology who need a comprehensive, nursing process-aligned question bank for building course assessments at every level of clinical complexity.
💡 THE FIVE-LENS FRAMEWORK FOR PHARMACOLOGY MASTERY
Advanced pharmacology performance — on exams and in clinical practice — requires you to look at every drug through five lenses simultaneously. This framework is embedded in Lilley’s approach and is embedded in this test bank.
Lens One — Mechanism. How does this drug produce its effect? What receptor does it act on? What enzyme does it inhibit? What channel does it block or open? Understanding mechanism is the foundation from which adverse effects, contraindications, and drug interactions can be predicted and understood rather than memorized.
Lens Two — Therapeutic Indication. What is this drug for? What clinical condition does it treat? What is the expected therapeutic outcome and what is the timeline for seeing it? This lens is where pharmacology connects to disease management — and where the nursing assessment of therapeutic response is grounded.
Lens Three — Adverse Effects and Toxicity. What can go wrong? What are the most serious adverse effects? What are the early signs of toxicity? What is the therapeutic index? Which patient populations are at elevated risk? This lens is where nursing monitoring lives — and it is the lens most heavily tested on pharmacology examinations and on the NCLEX-RN.
Lens Four — Drug Interactions. What other medications, foods, supplements, or patient conditions alter this drug’s safety or efficacy? This lens is where polypharmacy becomes a clinical challenge — and where medication reconciliation, patient history gathering, and pre-administration assessment make the difference between a therapeutic outcome and a preventable harm.
Lens Five — Patient Education. What does the patient need to know to take this medication safely and effectively at home? What administration instructions matter? What symptoms should prompt the patient to contact their provider? What lifestyle modifications support the drug’s therapeutic effect or reduce its risk? This lens is where nursing extends beyond the bedside into patient-centered care — and it is tested consistently on both course examinations and the NCLEX-RN.
Work through every question in this test bank with all five lenses in mind. Over time they become automatic. That is the point.
📝 10 SAMPLE QUESTIONS
These are real questions from the full test bank. They reflect the clinical scenario format, nursing process framework, and pharmacological depth of the complete product.
Question 1
A nurse is preparing to administer intravenous vancomycin to a patient with a methicillin-resistant Staphylococcus aureus wound infection. The ordered infusion rate is 1000 mg over 60 minutes. During the infusion, the patient develops sudden flushing of the face, neck, and chest, accompanied by itching and a mild drop in blood pressure. What is the nurse’s priority action?
- A. Stop the infusion immediately and administer epinephrine for anaphylaxis
- B. Slow the infusion rate significantly, administer diphenhydramine as prescribed, and monitor the patient closely
- C. Continue the infusion at the current rate and reassure the patient that flushing is a minor side effect
- D. Discontinue vancomycin and notify the prescriber that the patient has developed a drug allergy
Correct Answer: B Rationale: The clinical picture — flushing of the face, neck, and chest, pruritus, and mild hypotension during vancomycin infusion — is classic Red Man Syndrome. This is not an allergic reaction or anaphylaxis — it is an infusion rate-dependent adverse effect caused by histamine release triggered by excessively rapid vancomycin administration. It is prevented and treated by slowing the infusion rate and, when symptomatic, administering antihistamines. The correct infusion rate for vancomycin is no faster than 10 mg per minute — 1000 mg should infuse over a minimum of 60 minutes and ideally longer in patients with a prior history of Red Man Syndrome. Stopping the infusion entirely and administering epinephrine is the correct response to anaphylaxis — not Red Man Syndrome. Labeling this as a drug allergy is clinically inaccurate and could inappropriately restrict future vancomycin use in a patient who actually needs it.
Question 2
A nurse is reviewing the medication administration record for a patient who was just admitted from the emergency department with a diagnosis of digoxin toxicity. The patient’s serum digoxin level is 3.2 ng/mL. Which finding in the patient’s current assessment is most consistent with digoxin toxicity?
- A. Blood pressure of 148/92 mmHg and bounding peripheral pulses
- B. Visual disturbances including yellow-green halos around lights, nausea, and heart rate of 48 bpm
- C. Dry cough, bilateral ankle edema, and creatinine of 1.1 mg/dL
- D. Headache, flushing, and heart rate of 110 bpm
Correct Answer: B Rationale: The therapeutic range for digoxin is 0.5 to 2.0 ng/mL for heart failure management. A level of 3.2 ng/mL is clearly toxic. Classic signs of digoxin toxicity include gastrointestinal symptoms — nausea, vomiting, anorexia — and characteristic visual disturbances, including yellow-green visual halos, blurred vision, and photophobia. Bradycardia and various dysrhythmias — particularly AV block and ventricular dysrhythmias — are the most dangerous manifestations of cardiac toxicity. Hypokalaemia significantly increases digoxin toxicity risk by increasing myocardial sensitivity to the drug. Options A and D describe findings inconsistent with digoxin toxicity. The dry cough and edema in option C suggest ACE inhibitor side effect and volume overload respectively — not digoxin toxicity specifically.
Question 3
A nurse is preparing discharge teaching for a patient who has been newly prescribed warfarin for atrial fibrillation. Which statement made by the patient indicates a need for further teaching?
- A. “I will have my INR checked regularly as my doctor orders.”
- B. “I should eat the same amount of foods containing vitamin K each week rather than suddenly changing my intake.”
- C. “I can take ibuprofen for headaches as long as I stay within the recommended dose.”
- D. “I should tell any new healthcare provider that I take warfarin before any procedure.”
Correct Answer: C Rationale: NSAIDs including ibuprofen significantly increase bleeding risk in patients on warfarin through two mechanisms — antiplatelet effects that impair clot formation and GI mucosal irritation that increases bleeding risk. Patients on warfarin must avoid NSAIDs and use acetaminophen for pain management instead, within recommended dosing limits. Consistent vitamin K intake is correct — sudden changes in dietary vitamin K alter warfarin’s anticoagulant effect. Regular INR monitoring is essential for safe warfarin management. Disclosure to all providers is critical since many medications, procedures, and supplements interact with warfarin. The patient’s statement about ibuprofen demonstrates a specific, clinically dangerous misunderstanding that requires immediate correction.
Question 4
A nurse is caring for a patient receiving a continuous heparin infusion for deep vein thrombosis. The aPTT result returns at 210 seconds. The patient’s baseline aPTT was 28 seconds. The therapeutic target is 60 to 100 seconds. What is the nurse’s priority action?
- A. Continue the infusion at the current rate — this level of anticoagulation is acceptable for DVT treatment
- B. Increase the heparin infusion rate to achieve faster therapeutic anticoagulation
- C. Stop the heparin infusion, notify the prescriber immediately, and assess the patient for signs of bleeding
- D. Administer protamine sulfate immediately without waiting for provider notification
Correct Answer: C Rationale: An aPTT of 210 seconds is significantly supratherapeutic — more than seven times the patient’s baseline and more than twice the upper limit of the therapeutic range. This represents severe over-anticoagulation and carries a high risk of serious haemorrhage. The immediate nursing actions are to stop the infusion, notify the prescriber urgently, and perform a head-to-toe assessment for bleeding signs including neurological assessment for intracranial haemorrhage, abdominal assessment for internal bleeding, and assessment of all IV sites, urine, and stool. Protamine sulfate is the reversal agent for heparin but must be ordered by a prescriber — it is not administered on nursing initiative alone. Continuing or increasing the infusion at this aPTT level would cause serious harm.
Question 5
A patient with type 2 diabetes has been started on metformin 500 mg twice daily. Two weeks later, the patient is scheduled for a CT scan with intravenous contrast. What is the most important nursing action related to the patient’s metformin therapy prior to this procedure?
- A. Administer the patient’s scheduled metformin dose on the morning of the CT scan to maintain glycaemic control during the procedure
- B. Hold the metformin before the procedure and for 48 hours after, pending assessment of renal function following contrast administration
- C. Switch the patient to insulin therapy permanently since metformin must be discontinued for all imaging procedures
- D. Reassure the patient that metformin is safe to continue since it is a low-risk oral antidiabetic drug
Correct Answer: B Rationale: Iodinated intravenous contrast agents can cause acute kidney injury, particularly in patients with risk factors. Metformin is renally cleared and if renal function is impaired — whether pre-existing or contrast-induced — metformin accumulates to potentially toxic levels, increasing the risk of lactic acidosis, a rare but life-threatening complication. Current guidelines recommend holding metformin at the time of or prior to contrast-enhanced procedures and not restarting it until renal function has been reassessed and confirmed stable — typically at 48 hours post-procedure. This is not a reason to permanently discontinue metformin. The nurse must ensure the radiological team and prescriber are aware of the patient’s metformin therapy and that the hold-and-reassess protocol is in place.
Question 6
A nurse is administering phenytoin intravenously to a patient in status epilepticus. Which nursing action is most critical during IV phenytoin administration?
- A. Administer phenytoin diluted in dextrose 5% in water to prevent precipitation
- B. Infuse phenytoin at the maximum rate possible to achieve rapid seizure control
- C. Administer phenytoin at a rate no faster than 50 mg per minute with continuous cardiac monitoring and frequent blood pressure assessment
- D. Mix phenytoin with normal saline in a volume of 50 mL and infuse over 10 minutes
Correct Answer: C Rationale: IV phenytoin administration carries serious cardiovascular risks — hypotension, bradycardia, and potentially fatal cardiac dysrhythmias — when administered too rapidly. The maximum safe infusion rate is 50 mg per minute in adults, with slower rates recommended in older adults and patients with known cardiac disease. Continuous cardiac monitoring and frequent blood pressure assessment are mandatory throughout infusion. Phenytoin must never be diluted in dextrose-containing solutions because it precipitates in the presence of glucose — normal saline is the only compatible IV diluent. Fosphenytoin, a phenytoin prodrug, can be infused faster and is preferred in many clinical settings for IV use. The nurse must understand these specific administration requirements — phenytoin is a high-alert medication where administration errors have caused cardiac arrest.
Question 7
A nurse is providing medication education to a patient newly prescribed alendronate for osteoporosis. Which instruction is most important to include?
- A. “Take this medication at bedtime with a large glass of milk to improve absorption.”
- B. “You may take this medication with your morning coffee or tea if it upsets your stomach.”
- C. “Take this medication first thing in the morning with a full glass of plain water, remain upright for at least 30 minutes, and wait 30 minutes before eating or drinking anything else.”
- D. “This medication can be crushed and mixed with food if swallowing tablets is difficult for you.”
Correct Answer: C Rationale: Bisphosphonates including alendronate have strict administration requirements that are essential for both efficacy and safety. The drug is poorly absorbed in the presence of any food, beverage other than plain water, or other medications — it must be taken on an empty stomach with plain water only. Remaining upright for at least 30 minutes after administration prevents the tablet from sitting in the esophagus, where its highly caustic nature can cause severe esophageal irritation, erosion, and ulceration. These are not optional recommendations — they are safety requirements. Milk and coffee both contain substances that prevent absorption. Crushing the tablet eliminates the enteric protection and dramatically increases esophageal damage risk. Patient education on these specific requirements directly determines whether alendronate is safe to use.
Question 8
A nurse is caring for a patient who received morphine 4 mg IV 20 minutes ago for post-operative pain. The patient’s current respiratory rate is 8 breaths per minute, oxygen saturation is 90% on room air, and the patient is difficult to rouse. What is the nurse’s immediate priority?
- A. Administer the next scheduled dose of morphine since the patient’s pain may not be adequately controlled
- B. Apply supplemental oxygen, stimulate the patient, call for help, prepare naloxone for administration, and notify the provider urgently
- C. Document the respiratory rate and oxygen saturation and reassess in 30 minutes
- D. Position the patient in the prone position to improve respiratory effort
Correct Answer: B Rationale: This clinical picture — respiratory rate of 8 bpm, oxygen saturation of 90%, and difficult to rouse 20 minutes after IV morphine — is opioid-induced respiratory depression, a potentially fatal adverse effect of opioid analgesia that requires immediate intervention. The nurse must simultaneously apply supplemental oxygen, stimulate the patient with sternal rub or loud voice, call for immediate assistance, prepare naloxone for administration per protocol or provider order, and urgently notify the provider. Naloxone — the opioid reversal agent — rapidly reverses respiratory depression but has a shorter half-life than most opioids, requiring close monitoring for re-narcotization. Administering additional morphine would be catastrophically harmful. Documentation and reassessment in 30 minutes are wholly inadequate responses to an acute emergency. Prone positioning does not address the pharmacological cause of respiratory depression.
Question 9
A nurse is reviewing morning laboratory results for a patient on furosemide 40 mg daily for heart failure. The serum potassium is 3.1 mEq/L. The patient reports leg cramps and is on digoxin 0.125 mg daily. What is the priority nursing action?
- A. Administer the scheduled furosemide and digoxin doses and monitor the patient throughout the shift
- B. Hold the furosemide, administer the digoxin, and notify the provider of the potassium level
- C. Hold both furosemide and digoxin, notify the provider urgently of the potassium level and the patient’s symptoms, and prepare for potassium replacement
- D. Reassure the patient that leg cramps are a common and harmless side effect of furosemide therapy
Correct Answer: C Rationale: A serum potassium of 3.1 mEq/L is hypokalaemia — clinically significant on its own, but particularly dangerous in a patient on digoxin. Hypokalaemia dramatically potentiates digoxin toxicity by increasing myocardial sensitivity to the drug, meaning a digoxin level that would be therapeutic at a normal potassium can become toxic at a low potassium. Administering digoxin to a hypokalaemic patient carries serious risk of life-threatening dysrhythmias. Furosemide — a loop diuretic — causes potassium wasting and is the likely cause of the hypokalaemia. Both drugs must be held. The provider must be notified urgently — not at the next routine opportunity — because this combination of findings represents a clinical emergency requiring potassium replacement and medication reassessment. The leg cramps are a symptom of hypokalaemia, not a minor nuisance.
Question 10
A nurse is preparing to administer the morning medications for a patient with Parkinson’s disease who is nil by mouth in preparation for a colonoscopy. The patient’s medications include levodopa-carbidopa 25/100 mg three times daily. The colonoscopy is scheduled for 10 AM and the morning dose is due at 8 AM. What is the most appropriate nursing action?
- A. Hold all medications as ordered since the patient is nil by mouth before the procedure
- B. Recognise that abrupt withdrawal of levodopa-carbidopa can precipitate a life-threatening neuroleptic malignant syndrome-like crisis and consult the neurologist and procedural team to arrange for the dose to be given with a minimal sip of water or discuss alternative administration
- C. Crush the levodopa-carbidopa tablet and administer it mixed into the patient’s IV fluid
- D. Administer the dose at the usual time since NPO status does not apply to essential medications
Correct Answer: B Rationale: Levodopa-carbidopa is one of a specific category of medications — along with anticonvulsants, cardiac medications, and immunosuppressants — where abrupt discontinuation carries a risk that significantly outweighs the aspiration risk of a small sip of water before an elective procedure. Sudden withdrawal of levodopa in a Parkinson’s patient can cause a severe withdrawal syndrome resembling neuroleptic malignant syndrome — hyperthermia, severe rigidity, altered consciousness, and autonomic instability — which is potentially fatal. The nurse must not make an independent decision to either give or withhold this medication without consulting the neurologist and the procedural team. The standard approach is to administer with the absolute minimum amount of water required to swallow the tablet, which is generally accepted as not violating NPO requirements for elective procedures. Crushing levodopa-carbidopa tablets is inappropriate — the extended release formulations must not be crushed. This question tests the nursing knowledge that not all medications are equally safe to withhold and that NPO orders require clinical judgment, not automatic blanket application.
4 STUDY STRATEGIES BUILT FOR PHARMACOLOGY MASTERY
The Drug Class Architecture Method
Before you work through questions on any drug class, build a one-page architecture for that class. At the top — mechanism. Below that — the prototype drug and its clinical profile. Then — class-wide adverse effects and contraindications. Then — the nursing monitoring priorities that apply to every drug in the class. Then — patient education essentials. This architecture becomes your mental template. When you encounter a question about a specific drug within a class you have mapped, you can apply the template even when the specific drug detail is unfamiliar. Drug classes have internal logic. Use it.
The Five Rights Extension Drill
Most pharmacology questions that involve implementation can be answered by systematically applying an extended version of the rights of medication administration. Right patient — have you confirmed identity? Right drug — are there look-alike sound-alike concerns? Right dose — is this weight-appropriate, renal-adjusted, age-appropriate? Right route — is this route appropriate for this patient’s current condition? Right time — is there a timing requirement related to food, other medications, or physiological state? Right documentation — what needs to be recorded and when? Right to refuse — does the patient understand the medication and their options? Running through this checklist before answering implementation questions catches errors in your reasoning before they become errors on an exam.
The Adverse Effect Depth Protocol
For every major adverse effect you encounter in this test bank, ask four questions. One — how early or late does this appear relative to starting the medication? Two — what specific monitoring detects it before it becomes dangerous? Three — what are the specific nursing actions when it is detected? Four — what patient education would have allowed earlier identification? Adverse effect management is the most heavily tested pharmacology application in nursing examinations. Going four levels deep on every significant adverse effect produces the kind of clinical pharmacological knowledge that distinguishes high-performing students from average ones.
The Toxicity versus Side Effect Distinction
One of the most consistently valuable distinctions in pharmacology is the difference between a side effect — a predictable, dose-dependent, manageable effect — and toxicity — a dangerous, sometimes life-threatening accumulation of drug effect that requires immediate action. Lithium’s hand tremor is a side effect at 0.8 mEq/L. Coarse tremor, confusion, and nausea at 1.8 mEq/L is toxicity. Vancomycin’s red man syndrome is an infusion rate-related reaction, not allergy or toxicity. Vancomycin nephrotoxicity is organ toxicity requiring dose adjustment. Building this distinction for every high-alert drug in your pharmacology course produces the clinical judgment that makes toxicity recognition automatic on exam day and potentially lifesaving in practice.
❓ FREQUENTLY ASKED QUESTIONS
Is this the official Elsevier publisher test bank for the 11th edition? No. This is an independently developed study resource. It is not affiliated with Elsevier or the authors of Pharmacology and the Nursing Process. It is a supplementary product designed to support students and educators using the 11th edition.
My pharmacology course uses a different edition of Lilley. Will this test bank still be useful? The core pharmacological principles, drug classes, nursing process framework, and clinical reasoning skills tested in this test bank are consistent across editions of Pharmacology and the Nursing Process. Specific drug names, dose recommendations, and guideline references are built around the 11th edition. If you are using an earlier edition, the majority of the content will remain relevant, but some specific details may differ.
What formats are included with my purchase? Both PDF and Word formats are included. PDF is ideal for reading on any device without formatting disruption. Word allows you to select questions by drug class or chapter, adapt clinical scenarios for your patient population, and build course assessments if you are a faculty member.
How quickly will I receive my file after purchasing? Your download link is sent to your email automatically the moment your payment is confirmed. No manual processing is involved. Most students have their file open within minutes of completing checkout.
Is this test bank useful for the NCLEX-RN? Strongly yes. Pharmacological and parenteral therapies is one of the most heavily weighted content areas on the NCLEX-RN, consistently accounting for a significant proportion of questions across the exam. The clinical scenario format, nursing process framework, and drug class coverage in this test bank directly reflect the kind of pharmacology reasoning the NCLEX-RN tests.
I am preparing for a pharmacology-intensive specialty such as critical care or oncology nursing. Will this test bank address that depth? Yes. The units on cardiovascular pharmacology, antineoplastic drugs, anti-infective drugs, and emergency pharmacology are written to a level of clinical depth appropriate for specialty nursing preparation. The antineoplastic unit in particular covers safe handling, drug-specific toxicities, and oncological emergency management at a level useful for nurses entering oncology settings.
Can nursing faculty use this test bank for course examinations? Absolutely. All questions include correct answers and detailed rationales. The Word format makes it straightforward to select questions by drug class, adapt clinical scenarios for your institution’s patient population, and organize questions into structured course examinations at any level of clinical complexity.
What if something is wrong with my file or my order? Contact our support team directly with your order details and a description of the issue. We respond promptly and resolve every problem without delay or hassle. Your access to this resource should be seamless from the moment of purchase.
🏁 THE BOTTOM LINE ON PHARMACOLOGY
Here is what every nursing student discovers at some point in their pharmacology course — and the ones who discover it early have a significant advantage.
Pharmacology is not a memory course. It never was.
It is a reasoning course that uses memory as its raw material. The facts you memorize — the mechanisms, the adverse effects, the monitoring parameters, the patient education points — are not the goal. They are the inputs into clinical reasoning. The goal is the moment in a clinical encounter when all of those inputs organize themselves automatically into a clear picture of what the nurse should do and why.
That moment does not come from highlighting a textbook. It comes from practicing the reasoning — question after question, scenario after scenario — until the pattern recognition is built into how you think.
Lilley’s 11th Edition gives you the knowledge. This test bank gives you the practice. Together they give you what pharmacology is actually trying to produce — a nurse who thinks clearly about drugs because they understand them deeply.
That is the nurse every patient deserves. That is the nurse you are building yourself into.
Norah Helen –
Perfect
Lucille Maria –
I like it
Peterson S. –
Exactly what I need